Navigation Links
PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
Date:1/15/2014

NEW YORK, Jan. 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

Summary Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from GlobalData's July 2013 survey suggests a highly crowded, genericized market.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guideli
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Alzheimers Disease - China Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
10. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
11. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 The National Association of Managed ... released the NAMCP Medical Technologies Dossier Template © ... © , which provide medical directors and manufacturers ... devices or diagnostics that accounts for evidence-based development ... technology types (instead of having to attempt to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
Breaking Medicine Technology:NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... Mass., Oct. 26 DUSA Pharmaceuticals, Inc.® (Nasdaq: ... dermatology announced today that it has been named to ... consecutive year, Deloitte recognized DUSA as one of the ... and clean technology companies in North America.  Rankings are ...
... Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop... -- INGELHEIM, Germany and ROCKVILLE, Md., Oct. 26 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 3Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 4Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 5Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 6Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 7Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 8Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 9Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 10
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
(Date:9/16/2014)... Dennis Thompson HealthDay ... -- A combination drug therapy aimed at opening the ... treatment for older adults with chronic obstructive pulmonary disease ... COPD patients who received a combination of ... to die or require hospitalization because of their breathing ...
(Date:9/16/2014)... York (PRWEB) September 16, 2014 ... filed against C.R. Bard, Inc. continue to move ... U.S. District Court, Southern District of West Virginia, ... dated September 15, 2014, the Court has determined ... to the proceeding. The Order indicates that the ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Novatus, a ... a new office in London, UK, and appointed Jim ... in Europe, the expansion will allow Novatus to target ... its European customers. , “Novatus is ... and London is an ideal location to establish our ...
(Date:9/16/2014)... The child molestation victim lawyers at Estey ... who, according to case documents, were allegedly sexually abused ... San Diego. The victims were allegedly in elementary school ... of the defendant in the case remains confidential, per ... noted that no criminal charges were filed against the ...
Breaking Medicine News(10 mins):Health News: Most Treatments for Blood Clots Appear Safe, Effective 2Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:ESTEY BOMBERGER Announces $3 Million Settlement for Sexual Abuse at San Diego Private School 2
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. (CTI) ... Drug Administration (FDA) has accepted and has filed for review the ... or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User Fee ... review of the pixantrone NDA by September 4th 2009. ...
... at the time of diagnosis do not live as long ... conclusion of a new study to be published in the ... journal of the American Cancer Society. The authors of the ... marital separation may compromise an individual,s immune system and lead ...
... factor for active tuberculosis (TB) disease, according to a new ... analyzed data from nearly 17,000 individuals in Taiwan as part ... past studies have reported increased mortality among TB patients who ... effect of smoking on active TB incidence using a longitudinal ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Over one-hundred business ... , ... -- Rooted in Newtonian and quantum science, ancient spiritual and healing traditions, and clinical studies, ... book ColorAlchemy , by Jami Lin teaches people how to harness a daily color ...
... diagnosis of Idiopathic Pulmonary Fibrosis is not much better ... the survival rate is less than three years. ... that targeting of a novel gene utilizing genetic and ... mice and will be developed for future testing in ...
Cached Medicine News:Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:Smoking increases risk of developing active TB 2Health News:Smoking increases risk of developing active TB 3Health News:New technique can help diagnose mesothelioma 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 3Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 4Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2
... System is a point-of-care system designed for ... referred to as Platelet Rich Plasma - ... a small sample of blood. The Symphony ... factors, which are found in the platelets. ...
... Dual Imaging Color Module Leica combines precision microscopy ... important and necessary patient data can be displayed ... optical platform on the Leica OH3, OHS1, MS3 ... highest brightness, contrast >300:1, true color and resolution ...
... Headlight mounted micro video camera has ... pictures in areas otherwise invisible to all ... capabilities. The system may be used for ... eliminating crowding of the sterile area and ...
... DXC-S500 consists of 2-piece body, one is CHU ... and built-in Peltier cooling devices, the other is ... monitor. CCU incorporates IEEE1394 interface for direct connection ... card slot for storing images into memory stick ...
Medicine Products: